Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for rare skin cancer in early trial

NCT ID NCT05944562

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, and whether it can help control the disease. Because it is a Phase 1 trial, the main focus is on safety and finding the right dose, not yet on proving effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tulmimetostat (DZR123), a drug taken by mouth
What this could lead to
If this works, it could point toward a new treatment option for advanced mycosis fungoides and Sézary syndrome, potentially helping control the disease.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES MYCOSIS FUNGOIDES/SEZARY SYNDROME SEZARY SYNDROME

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.